Repligen Corp (RGEN) 15.84 $RGEN
Repligen Corporation Set to Join the S&P SmallCap 600
PR Newswire - Tue Apr 15, 4:53PM CDT
Repligen Corporation (NASD:RGEN) will replace Hi-Tech Pharmacal Co., Inc. (NASD:HITK) in the S&P SmallCap 600 after the close of trading on Thursday, April 17. S&P SmallCap 600 constituent Akorn Inc. (NASD:AKRX) is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Top Gainers on the Move -- Research on Banco Bradesco, RadNet, Repligen, and B&G Foods
PR Newswire - Tue Apr 08, 9:17AM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 declined 1.08%, to finish the trading session at 1,845.04. The session witnessed selling pressure in the Consumer Discretionary, Financials, and Energy sectors that negatively impacted the broader market. A number of stocks saw large movements, including Banco Bradesco S.A. (NYSE: BBD), RadNet Inc. (NASDAQ: RDNT), Repligen Corp. (NASDAQ: RGEN) and B&G Foods Inc. (NYSE: BGS). Free technical research on BBD, RDNT, RGEN and BGS can be downloaded upon signing up at:
3 Stocks Spiking on Unusual Volume
at The Street - Tue Apr 08, 7:05AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Repligen Shares Down 10.8% Since SmarTrend's Sell Call (RGEN)
Comtex SmarTrend(R) - Mon Mar 31, 9:32AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on March 6th, 2014 at $14.02. In approximately 4 weeks, Repligen has returned 10.77% as of today's recent price of $12.51.
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS 45 cm diameter columns ("OPUS 45"
with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego.
Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
Uptrend Call Working As Repligen Stock Rises 74.9% (RGEN)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 74.91% as of today's recent price of $14.92.
Repligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
GlobeNewswire - Tue Feb 25, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2013. In addition, the Company will provide financial guidance for its fiscal year 2014.
Repligen Has Returned 94.4% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Feb 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 94.40% as of today's recent price of $16.58.
Your Gadgets
by Patrick Buchana - All Africa Global Media - Thu Feb 20, 10:34PM CST
Gadget: Samsung Smart Gear
Repligen Has Returned 70.3% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 70.34% as of today's recent price of $14.53.
Commit To Buy Repligen Corp. At $12.50, Earn 12.8% Annualized Using Options
StockOptionsChannel.com - Mon Feb 03, 11:38AM CST
Investors eyeing a purchase of Repligen Corp. shares, but cautious about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Repligen Corporation Set to Join the S&P SmallCap 600
PR Newswire - Tue Apr 15, 4:53PM CDT
Repligen Corporation (NASD:RGEN) will replace Hi-Tech Pharmacal Co., Inc. (NASD:HITK) in the S&P SmallCap 600 after the close of trading on Thursday, April 17. S&P SmallCap 600 constituent Akorn Inc. (NASD:AKRX) is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Top Gainers on the Move -- Research on Banco Bradesco, RadNet, Repligen, and B&G Foods
PR Newswire - Tue Apr 08, 9:17AM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 declined 1.08%, to finish the trading session at 1,845.04. The session witnessed selling pressure in the Consumer Discretionary, Financials, and Energy sectors that negatively impacted the broader market. A number of stocks saw large movements, including Banco Bradesco S.A. (NYSE: BBD), RadNet Inc. (NASDAQ: RDNT), Repligen Corp. (NASDAQ: RGEN) and B&G Foods Inc. (NYSE: BGS). Free technical research on BBD, RDNT, RGEN and BGS can be downloaded upon signing up at:
3 Stocks Spiking on Unusual Volume
at The Street - Tue Apr 08, 7:05AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Repligen Shares Down 10.8% Since SmarTrend's Sell Call (RGEN)
Comtex SmarTrend(R) - Mon Mar 31, 9:32AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on March 6th, 2014 at $14.02. In approximately 4 weeks, Repligen has returned 10.77% as of today's recent price of $12.51.
Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective purification of biologic drugs, today announced the commercial launch of its OPUS 45 cm diameter columns ("OPUS 45"
with the largest capacity currently available on the market. OPUS columns, which now range from 1.2 cm to 45 cm in diameter, are delivered packed with chromatography media used to purify monoclonal antibodies and other biologic drugs. OPUS technology increases facility flexibility, improves the speed of process development and reduces the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies. OPUS 45 was designed to process large single-use bioreactor harvests and will be formally launched at Biopharmaceutical Development & Production Week being held March 24-27 at the Hilton Bayfront Hotel in San Diego. Repligen EPS plunges, misses
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The biotech said Q4 EPS fell nearly 67% to 10 cents, missing views by 4 cents. Revenue dipped 18.2% to $15.4 mil. Product gross margin widened to 55.3% from 39% in the year ago quarter. R&D expense fell 39.3%. Repligen (RGEN) sees '14 revenue of $54...
Why Repligen Corporation Shares Were Slammed
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 12:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repligen , a life-sciences company that...
Repligen Reports Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
- 2013 Product Revenue Growth of 13.5% -
Uptrend Call Working As Repligen Stock Rises 74.9% (RGEN)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 74.91% as of today's recent price of $14.92.
Repligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results
GlobeNewswire - Tue Feb 25, 6:30AM CST
Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year 2013 financial results on Thursday, March 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting periods ended December 31, 2013. In addition, the Company will provide financial guidance for its fiscal year 2014.
Repligen Has Returned 94.4% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Feb 24, 9:13AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 8 months, Repligen has returned 94.40% as of today's recent price of $16.58.
Your Gadgets
by Patrick Buchana - All Africa Global Media - Thu Feb 20, 10:34PM CST
Gadget: Samsung Smart Gear
Repligen Has Returned 70.3% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on July 2nd, 2013 at $8.53. In approximately 7 months, Repligen has returned 70.34% as of today's recent price of $14.53.
Commit To Buy Repligen Corp. At $12.50, Earn 12.8% Annualized Using Options
StockOptionsChannel.com - Mon Feb 03, 11:38AM CST
Investors eyeing a purchase of Repligen Corp. shares, but cautious about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal.
